Aerobic Exercise and Heart Risk in People With Chronic Kidney Disease or Rheumatoid Arthritis
Tests an aerobic exercise program for heart risk in kidney disease or rheumatoid arthritis.
Key facts
- Who runs it
- Jérôme Bouchan
- Where
- Besançon, FranceSee the site
- Trial code
- Registry title
- Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 16 Mar 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Aerobic exercise program
- Therapeutic education
- Record updated
- 13 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with chronic kidney disease (stages III or IV, not on dialysis) or rheumatoid arthritis, to test an aerobic exercise program.
- Age
- 50 years or older
- Sex
- All sexes can join
- Disease stage
- Chronic kidney disease: glomerular filtration rate between 45 and 20 ml/min/1.73 m² (stages III and IV, not on dialysis). Rheumatoid arthritis: DAS 28 score of 2.6 points or more. No other disease-related risk factors.
- Earlier treatment
- Not on dialysis for people with kidney disease. A stable corticosteroid dose of 10 mg prednisone a day or less.
Main reasons for not taking part
- Unstable corticosteroid treatment or more than 10 mg prednisone a day
- Uncontrolled high blood pressure
- Pregnant women
- Cannot do physical exercise for any reason
- Cannot understand or follow an exercise program
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease
- Having a glomerular filtration rate between 45 and 20 ml/min/1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA
- Have a medical certificate stating that there are no adverse reactions to physical activity
- Affiliation with a French social security scheme or beneficiary of such a scheme
Who cannot take part
- Unstabilised corticosteroid therapy and/or >10mg prednisone/day
- Uncontrolled high blood pressure
- Pregnant women
- Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program
- Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal)
- Legal incapacity or limited legal capacity
- Subject unlikely to cooperate with the study and/or low cooperation anticipated by the investigator
- Subject without health insurance
- Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system
Where in France
- EPHI PlatformBesançon, FranceContact: Jérôme Bouchan, PhDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease.
Read full original descriptionShow less
The main questions this study aims to address are:
* Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ? * What are the effects of this exercise program on inflammation and immunosenescence?
Researchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention.
Participants will:
* Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve); * Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention; * Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.
The 3 groups in the trial
- Experimental groupTreatment being tested
Aerobic exercise program during 6 weeks (3 session / week), with 45 minutes ergocycle exercise
Treatment: Aerobic exercise program
- Physical activity oriented groupExisting treatment, for comparison
Therapeutic education during 6 weeks (1 phone call / week), with advice and exchanges to improve physical activity
Treatment: Therapeutic education
- Control groupNo study treatment, for comparison
No intervention group during 6 weeks, participants have to maintain their lifestyle
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis
- Plain-language title
- Aerobic Exercise and Heart Risk in People With Chronic Kidney Disease or Rheumatoid ArthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 March 2026